Observational studyEmerging infectious diseases2017
Disease Burden of Clostridium difficile Infections in Adults, Hong Kong, China, 2006-2014.
Observational study in Emerging infectious diseases, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- Epidemiologic profile of community-acquiredEpidemiology and infection · 2025Pooled it
- Review
- Changes in the Epidemiology of Clostridioides difficile Infection.Infectious disease clinics of North America · 2025Review
- Detection and Analysis ofInternational journal of environmental research and public health · 2022Article
- Vitamin DAutophagy · 2022Article
- Trends in Incidence and Clinical Outcomes of Clostridioides difficile Infection, Hong Kong.Emerging infectious diseases · 2021Article
- Outcomes of respiratory viral-bacterial co-infection in adult hospitalized patients.EClinicalMedicine · 2021Article
- Evaluation of the antimicrobial activity of ridinilazole and six comparators against Chinese, Japanese and South Korean strains of Clostridioides difficile.The Journal of antimicrobial chemotherapy · 2021Article
- Phylogenomic analysis of Clostridioides difficile ribotype 106 strains reveals novel genetic islands and emergent phenotypes.Scientific reports · 2020Article
- Association of Household Exposure to Primary Clostridioides difficile Infection With Secondary Infection in Family Members.JAMA network open · 2020Article
- Increased Community-Associated Clostridioides difficile Infections in Quebec, Canada, 2008-2015Emerging infectious diseases · 2020Article
- Colonization of ToxigenicFrontiers in cellular and infection microbiology · 2020Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cross-sectional studies suggest an increasing trend in incidence and relatively low recurrence rates of Clostridium difficile infections in Asia than in Europe and North America. The temporal trend of C. difficile infection in Asia is not completely understood. We conducted a territory-wide population-based observational study to investigate the burden and clinical outcomes in Hong Kong, China, over a 9-year period. A total of 15,753 cases were identified, including 14,402 (91.4%) healthcare-associated cases and 817 (5.1%) community-associated cases. After adjustment for diagnostic test, we found that incidence increased from 15.41 cases/100,000 persons in 2006 to 36.31 cases/100,000 persons in 2014, an annual increase of 26%. This increase was associated with elderly patients, for whom incidence increased 3-fold over the period. Recurrence at 60 days increased from 5.7% in 2006 to 9.1% in 2014 (p<0.001). Our data suggest the need for further surveillance, especially in Asia, which contains ≈60% of the world's population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.